Tradestie Institutional Equity Comparison Engine
XLO vs STLN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XLO Overall Edge
XLO Captures Institutional Edge (3โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xilio Therapeutics, Inc. Common Stock (XLO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, XLO trades at N/M Forward P/E with -74.9% operating margin (-47.6% YoY revenue) versus STLN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
XLO
XLO N/M vs STLN N/M Fwd P/E
Growth & Margin Winner
XLO
Op Margin -74.9% vs N/A ยท YoY -47.6% vs N/A
Momentum & Technical Winner
XLO
1Y +836.8% vs -42.0% ยท 52W Pos 75% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XLO
NASDAQ
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap
$53.1M
1M Return
-5.85%
1Y Return
+836.8%
Forward P/E
N/M
Unified AI Score
45.8 / 100
HOLD
Tech 40.0
Fund 50.0
Flow 50.0
Mom 74.0
STLN
US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap
N/A
1M Return
-56.58%
1Y Return
-41.97%
Forward P/E
N/M
Unified AI Score
46.6 / 100
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XLO +836.8%
STLN -41.97%
Spread: +25.14 pp (XLO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
XLO TTM Op. Margin: -74.9%
STLN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLO vs STLN. Trailing 12-month operating profitability (XLO -74.9% vs STLN N/A) and valuation multiples (XLO N/M vs STLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XLO | STLN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $53.1M | N/A | Larger Scale | XLO |
| Trailing P/E Ratio Valuation | 11.6x | N/M | Lower Multiple | XLO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -47.6% | N/A | Higher Growth | XLO |
| Operating Margin (TTM) Profitability | -74.9% | N/A | Higher Margin | XLO |
| Net Profit Margin Profitability | -20.9% | N/A | Higher Margin | XLO |
| Return on Equity (ROE) Capital Efficiency | -38.2% | N/A | Higher ROE | XLO |
| 52-Week Range Position Momentum | 75% ($0โ$10) | 1% ($3โ$7) | Stronger Trend | XLO |
| Beta / 30D Volatility Risk Regime | 0.74ฮฒ ยท 63% Vol | 1.42ฮฒ ยท 175% Vol | Lower Realized Risk | XLO |
| Unified Institutional Score Composite Signal | 45.8 / 100 (HOLD) | 46.6 / 100 (HOLD) | Higher Composite | STLN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XLO vs STLN Buy Guide
XLO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
STLN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XLO nor STLN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.